Jefferies Financial Group’s Stoke Therapeutics STOK Stock Holding History

Jefferies Financial Group’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$531K	Buy	+16,300	New	+$535K	﹤0.01%	1185

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Jefferies Financial Group's STOK Position: Q1 2026 in Review

Jefferies Financial Group opened a new position in Stoke Therapeutics (STOK) in Q1 2026: 16,300 shares worth $531K. The stake represents ﹤0.01% of the portfolio and ranks #1185 among its holdings.

196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

Jefferies Financial Group held 16,300 shares of Stoke Therapeutics worth $531K as of Q1 2026.
Stoke Therapeutics was a new Jefferies Financial Group position in Q1 2026.
Stoke Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1185 holding.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.